Healthcare / BiotechnologyNasdaqGM
$4.90
-0.37 (-7.02%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-20.7M · quality 67.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
26/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$117M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-55.1%
↓Gross Margin
N/A
•Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2019–2025 · 6 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.89x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-43.4M · FCF $-38.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | — | — | — | — | — | — | — | $165000.00 |
| Net Income | $-43.4M | $-43.4M | $-69.2M | $-14.7M | $-15.5M | $-172.0M | $-69.8M | $-23.8M |
| EBITDA | $-42.0M | $-42.0M | $-66.5M | $-14.0M | $-15.3M | $-169.6M | $-71.2M | $-26.7M |
| EPS | -2.85 | -2.85 | -3.70 | -11.05 | -11.64 | -63.02 | — | — |
| Operating Margin | — | — | — | — | — | — | — | -16182.4% |
| Net Margin | — | — | — | — | — | — | — | -14447.9% |
| Balance Sheet | ||||||||
| Debt/Equity | 0.02 | 0.02 | -0.20 | — | -0.11 | — | — | — |
| Current Ratio | 12.19 | 12.19 | — | — | — | — | — | — |
| Cash Flow | ||||||||
| Free Cash Flow | $-38.6M | $-38.6M | $-20.7M | $-14.1M | $-9.8M | $-106.3M | $-61.0M | $-20.5M |
| Returns | ||||||||
| ROE | -55.1% | -55.1% | 71.6% | 32.7% | 51.2% | -76.3% | -19.8% | 46.3% |
| Valuation | ||||||||
| P/B | 0.95 | 0.95 | — | — | — | — | — | — |
| Growth & Yield | ||||||||
| EPS Growth | 23.1% | 23.1% | 66.5% | 5.1% | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+69.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-3.70 → -2.85
Residual
+69.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.